CCND1 and cancer: In the analysis stratified for cancer site, a significantly increased risk was found of lymph node positive (HR: 1.81 95% CI: 1.00-3.28) and non-metastatic disease (HR: 1.55; 95% CI: 1.00-2.40), as well as for cyclin D1 positive tumours (HR: 1.62 95% CI: 1.04-2.51) in the colon (Table 7).